Oxybutynin and the overactive bladder

doi:10.1007/PL00007103

Paper

Oxybutynin and the overactive bladder

Published Nov 1, 2001 · K.-E. Andersson, Christopher R. Chapple

World Journal of Urology

Q1 SJR score

76

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract Oxybutynin is a tertiary amine, which undergoes an extensive first-pass metabolism. It has an active metabolite, N-desethyl oxybutynin, and the effect of oral oxybutynin is to a large extent exerted by this metabolite. Oxybutynin has both an antimuscarinic and a direct muscle relaxant effect, and, in addition, local anesthetic actions. Most probably, oral oxybutynin exerts its effects on the overactive bladder (OAB) by an antimuscarinic action. Several studies have shown that oral oxybutynin is effective in controlling OAB. Admininistred intravesically, it can increase bladder capacity and produce clinical improvement both in patients with hypereflexia and in other types of OAB with few side effects. Adverse effects related to the antimuscarinic activity occur frequently and can necessitate treatment discontinuation in up to 25% of patients, depending on the dosage. A controlled-release preparation has recently been introduced. Oxybutynin has a well-documented efficacy in the treatment of detrusor overactivity, and is a drug of first choice in patients with this disorder.

Highly Cited

Study Snapshot

Oral oxybutynin effectively controls overactive bladder, increasing bladder capacity and improving clinical improvement in patients with hypereflexia and other types of OAB, with few side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Oxybutynin and the overactive bladder

Sign up to use Study Snapshot

References

Citations

The Long-Term, Real-World Effects of Oxybutynin on Pressure Reservoir Function in the Neurogenic Bladder after Spinal Cord Injury: A Retrospective Cohort Study

High-dose oxybutynin and oxybutynin-trospium combination significantly reduce maximal detrusor pressure in patients with neurogenic bladder after spinal cord injury, with sustained effects across three follow-up periods.

Short‑term effects of oxybutynin dosage in individuals with neurogenic bladder following spinal cord injury: A retrospective cohort study

Oxybutynin is clinically effective for managing neurogenic bladder in patients with spinal cord injury, with each 1 mg increase in dose leading to a mean decrease in detrusor pressure.

Transcutaneous neuromodulation versus oxybutynin for neurogenic detrusor overactivity in persons with spinal cord injury: A randomized, investigator blinded, parallel group, non-inferiority controlled trial.

Transcutaneous neuromodulation and oral oxybutynin effectively increased bladder capacity in persons with spinal cord injury with neurogenic detrusor overactivity, with neuromodulation being non-inferior to thrice-a-day oxybutynin when evaluated by one-channel water cystometry.

Open label, pilot evaluation of the safety and efficacy of Intravesical sustained release system of lidocaine and oxybutynin (TRG-100) for patients with interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive bladder (OAB) and patients with retained ureteral stents following Endourological

Intravesical TRG-100 is a safe and effective treatment for reducing pain and irritative bladder symptoms in patients with interstitial cystitis, overactive bladder, and retained ureteral stents.

Potential Role for Combined Subtype-Selective Targeting of M1 and M3 Muscarinic Receptors in Gastrointestinal and Liver Diseases

M1R activation may protect against gastrointestinal cancer progression, while M3R activation promotes it, offering potential therapeutic benefits for gastrointestinal and liver diseases.

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome

Botox is more cost-effective than oxybutynin for managing overactive bladder syndrome in adults, but less cost-effective in younger patients.

Current pharmacotherapy of overactive bladder

Individualizing pharmacological treatment for overactive bladder (OAB) is crucial, as each drug has specific pharmacologic properties, dosing schedule, and tolerability profile, requiring tailored approaches for patient characteristics and expectations.

Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review

Transdermal drug delivery shows the most potential for managing overactive bladder syndrome, with various other delivery routes showing potential for future research.